Biologische Hochschulschriften (Goethe-Universität)
Refine
Year of publication
Document Type
- Doctoral Thesis (852)
- Article (12)
- Part of Periodical (2)
- Bachelor Thesis (1)
- Diploma Thesis (1)
Has Fulltext
- yes (868)
Is part of the Bibliography
- no (868)
Keywords
- Gentherapie (7)
- NMR-Spektroskopie (6)
- gene therapy (6)
- Elektrophysiologie (5)
- Molekularbiologie (5)
- RNA (5)
- Schmerz (5)
- Apoptosis (4)
- Arzneimitteldesign (4)
- Carotinoide (4)
Institute
- Biowissenschaften (550)
- Biochemie und Chemie (169)
- Biochemie, Chemie und Pharmazie (79)
- Pharmazie (32)
- Institut für Ökologie, Evolution und Diversität (21)
- Georg-Speyer-Haus (6)
- Medizin (5)
- Geowissenschaften (4)
- Biodiversität und Klima Forschungszentrum (BiK-F) (3)
- Frankfurt Institute for Advanced Studies (FIAS) (3)
The functional and molecular role of transglutaminase 2 in hematopoietic stem and progenitor cells
(2023)
Long-term repopulating hematopoietic stem cells (LT-HSCs) that reside in the bone marrow (BM) give rise to all blood cell types including erythrocytes, leukocytes and platelets. LT-HSCs are mainly quiescent during steady state hematopoiesis. LT-HSCs can process self-renewal to expand and maintain stemness, or commit to differentiation into short-term (ST) repopulating HSC and multipotent progenitors (MPPs). MPPs differentiate into oligopotent lineagerestricted progenitors which eventually produce all mature blood cell lineages, and thereby regenerate hematopoietic system.
Previous studies have shown in transcription profiles and quantitative PCR (qPCR) analysis that transglutaminase 2 (Tgm2) is one of the most upregulated genes in quiescent LT-HSCs in comparison to active HSCs, mobilized HSCs, ST-HSCs, MPPs, as well as leukemic stem cells (LSC). However, the reason why Tgm2 is strongly upregulated in dormant mouse LTHSCs and what the role of Tgm2 is in LT-HSCs has not been investigated yet.
Tgm2, encoded by the Tgm2 gene, is a multi-functional protein within the transglutaminase family. It has been found to be widely expressed inside and outside the cells. It consists of four domains and two functionally exclusive forms that are regulated by the Ca2+ and GTP concentration. Besides the most well-known transglutaminase enzymatic activity for transamidation, deamidation and crosslinking, Tgm2 acts also as a GTPase/ATPase, kinase, adhesion/scaffold protein, as well as disulfide isomerase. The role of Tgm2 in hematopoiesis remains elusive. Accordingly, the aim of this dissertation is to investigate the role of Tgm2 in murine hematopoiesis, especially in murine LT-HSCs.
Firstly, the expression of Tgm2 was analyzed in highly purified murine hematopoietic stem and progenitor cell (HSPC) populations. Low input label-free mass spectrometric proteomics and WES protein analysis confirmed the highly specific expression of Tgm2 in LT-HSCs at protein level. Already at the state of MPPs, Tgm2 protein was almost absent with further decline towards oligopotent progenitors. These results indicated Tgm2 as a specific protein marker for LT-HSCs, justifying the future generation of a fluorescent reporter mouse line based on endogenous Tgm2 tagging.
To delineate the functional and molecular role of Tgm2 in LT-HSCs, a conditional Tgm2 knockout mouse model was generated using the Mx1-Cre/loxP system, with the loxP sites flanking the coding exons of the catalytic domain of Tgm2. After PolyIC-mediated induction, a more than 95% knockout efficiency was observed in purified LT-HSCs and the protein expression of Tgm2 was confirmed to be vanished in the purified LT-HSCs from conditional Tgm2-KO mice. Conditional knockout mice are viable and show no aberrant organ functions.
In steady state condition, the distribution of mature blood cell lineages and immunophenotypically-defined HSPC populations within the BM, the mitochondrial potential of HSPCs reflected by the non-invasive cationic dye JC-1, as well as the cell cycle status of HSPCs mirrored by the intracellular Ki67 staining did not show any significant variations upon loss of Tgm2. However, the in vitro continuous observation of prospectivly isolated LT-HSCs by time-lapse microscopy-based cell tracking revealed a delayed entry into cell cycle with a two fold increased apoptosis rate after knocking out Tgm2, indicating Tgm2 expression might be essential for survival of LT-HSCs. Moreover, while the absence of Tgm2 in LT-HSCs did not influence differentiation and lineage choice in vitro, overexpression of Tgm2 in LT-HSCs resulted in an increase of the most immature subpopulation upon cultivation. All these features were not observed in Tgm2-deleted MPPs, suggesting Tgm2 playing a specific function at the level of LT-HSCs. Upon stress hematopoiesis, induced by the administration of 5-fluorouracil (5-FU), there was a trend towards delayed recovery of LT-HSCs lacking Tgm2. Although Tgm2 express specificly in LT-HSCs, two rounds of competitive BM serial transplantation displayed an equal overall engraftment and multi-lineage reconstitution of LT-HSCs from Tgm2-WT and Tgm2-KO mice in peripheral blood (PB), BM and spleens. Interestingly, LT-HSCs from Tgm2-KO mice reconstituted to more myeloid cells and fewer B cells in the first four weeks after primary transplantation, which disappeared at later time points.
Gene expression profiling and simultaneous single cell proteo-genomic profiling indicated that HSPCs and LT-HSCs from Tgm2-KO mice were transcriptionally more active. A heterogeneity of Tgm2 expression within Tgm2-WT LT-HSCs was revealed by single cell data. Commonly up-regulated genes in Tgm2-KO LT-HSCs and MPPs were significantly involved in regulation of transcription from RNA polymerase II promoter in response to stress, positive regulation of cell death as well as negative regulation of mitogen-activated protein kinase (MAPK) signaling pathways. In Tgm2-KO LT-HSCs, 136 up-regulated genes demonstrated an enrichment of genes involved in apoptosis, as well as negative regulation of MAPK signaling pathway.
Taken together, this dissertation shows that Tgm2 protein is highly specifically expressed in LT-HSCs, but not in subsequent progenitor populations. However, Tgm2 is not essential for differentiation and maturation of myeloid lineages, the proliferation and the long-term multilineage reconstitution potential of LT-HSCs after transplantation. Tgm2 might be involved in accurate stress response of LT-HSCs and the transition from LT-HSCs into MPPs, meaning that the absence of Tgm2 results in poor survival, myeloid bias upon transplantation, as well as slower recovery upon chemotherapeutic treatment.
Nanoarzneimittel haben in den letzten Jahren in der Therapie verschiedener Erkrankungen immer mehr an Bedeutung gewonnen. Dadurch hat auch die Anzahl zugelassener Arzneimittel mit an Arzneistoffträgern wie Liposomen gebundenen Wirkstoffen zugenommen. Weil für die Zulassung, neben der Wirksamkeit und Unbedenklichkeit, auch die Qualität der neuen Arzneimittel gewährleistet sein muss, spielen die verschiedenen Eigenschaften der Arzneistoffträger eine wichtige Rolle in der Qualitätskontrolle. Neben der Partikelgröße, der Partikelgrößenverteilung und der Oberflächenladung spielt die (Rest-)Kristallinität des Wirkstoffs und die Wirkstofffreisetzung eine wesentliche Rolle für die erfolgreiche in vivo-Performance von Nanoarzneimitteln. Zur Bestimmung der Wirkstofffreisetzung aus kolloidalen Arzneistoffträgern wie Liposomen, Nanopartikeln oder Mizellen gibt es bis heute keine Standardmethoden. In der Forschung und der pharmazeutischen Industrie werden folglich verschiedene Methoden wie Filtration, Zentrifugation oder Dialyse verwendet, um den freigesetzten Wirkstoff zu bestimmen. Dabei ist die Wahl der Separationsmethode auf die Eigenschaften der Arzneistoffträger abzustimmen.
In der vorliegenden Arbeit wurde eine dialysebasierte Apparatur, der Dispersion Releaser (DR), zur Untersuchung der in vitro Wirkstofffreisetzung aus kolloidalen Trägersystemen eingesetzt. Diese kann direkt mit den Apparaturen I/II der Arzneibücher der Europäischen Union (Ph. Eur.) und der Vereinigten Staaten (USP) gekoppelt werden. Zur Untersuchung der Wirkstofffreisetzung wird die Formulierung in das Donorkompartiment gegeben, sodass der freigesetzte Wirkstoff infolge über die Dialysemembran in das Akzeptorkompartiment permeiert. Dort kann dieser mittels HPLC analysiert werden. Besonders hervorzuheben ist das synchrone Rühren in beiden Kompartimenten des DR, worüber andere dialysebasierte Apparaturen nicht verfügen.
Die Entwicklung und Patentierung eines funktionsfähigen Prototyps des DR erfolgte an der Goethe Universität, Frankfurt am Main und wurde im Rahmen dieser Arbeit gemeinsam mit der Pharma Test Apparatebau AG (Hainburg, Deutschland) zu einer kommerziell erwerbbaren Apparatur (Pharma Test Dispersion Releaser, PTDR) weiterentwickelt. Innerhalb dieser Kollaboration wurde der Prototyp des DR unter Einbezug der Anforderungen der pharmazeutischen Industrie rekonstruiert. Eine erleichterte Anwendung für den Nutzer wurde dabei mitberücksichtigt.
Die finale Apparatur wurde zuletzt einer ausgiebigen Validierung unterzogen, bei der Diclofenac und Hydrocortison als Modellarzneistoffe dienten. Neben Untersuchungen zur Hydrodynamik und dem Einfluss der Umdrehungszahl auf die Membranpermeationsrate kM wurde eine Methode mit Gold-Nanopartikeln zur Bestimmung der Dichtigkeit des Systems entwickelt. Hierbei wurden Messungen mit einer UV/Vis-Methode und mit dynamischer Lichtstreuung durchgeführt, um die Abwesenheit der Goldpartikel im Akzeptorkompartiment nachzuweisen. Der Einfluss von Proteinen im Freisetzungsmedium auf die Membran-permeation wurde ebenfalls untersucht.
Der DR wurde ursprünglich zur Untersuchung von parenteralen Nanoformulierungen entwickelt. Aufgrund der bisher noch nicht erfolgten Untersuchung von halbfesten Zubereitungen im DR, wurde die Apparatur im Rahmen dieser Forschungsarbeit für zwei verschiedene Diclofenac-Gele (Voltaren® Emulgel, Olfen® Gel) unter verschiedenen Bedingungen evaluiert. Dabei konnte unter non-sink-Bedingungen der Einfluss der lipophilen Phase des Voltaren® Emulgels (GlaxoSmithKline Consumer Healthcare GmbH & Co. KG, München, Deutschland) gezeigt werden. Im Vergleich zum fettfreien Olfen® Gel (Mepha Pharma AG, Basel, Schweiz) zeigte Voltaren® Emulgel eine vollständige Freisetzung unter den erschwerten Löslichkeitsbedingungen.
Mit Hydrocortison als Modellsubstanz wurden vier verschiedene Proliposomen zur vaginalen An¬wendung formuliert. Neben der Charakterisierung der Partikelgröße und der Verkapselungs¬effizienz wurden Messungen mit dynamischer Differenzkalorimetrie durch-geführt und Aufnahmen zur morphologischen Charakterisierung mittels Transmissions-elektronen¬mikroskopie der Liposomen erstellt. Die Wirkstofffreisetzung des Hydrocortisons aus dem rekonstituierten liposomalen Gel sowie die Permeabilität über eine Zellmonoschicht wurde vergleichend untersucht. Dabei wurden Zelllinien aus humanem Cervixkarzinom beziehungsweise Endometriumkarzinom eingesetzt. Die Unterschiede der Formulierungen konnten vom DR sensitiver erfasst werden und die Verkapselungseffizienz als relevanter Faktor für die in vivo-Performance festgelegt werden.
Weil die tatsächliche Wirkstofffreisetzung durch die Permeation über die Dialysemembran überlagert werden kann, wurde neben der Standardisierung der Konstruktion die Auswertung mit Hilfe eines neuen mathematischen Modells, das auf dem Fick’schen Diffusionsgesetz basiert, verbessert. Das Normalisieren des Freisetzungsprofils mit Hilfe des mathematischen Modells dient dazu, die tatsächliche Wirkstofffreisetzung zu berechnen und den Vergleich verschiedener Freisetzungen ohne den Einfluss der Membranpermeation zu ermöglichen. Im Zuge der Validierung des DR wurde das mathematische Modell ebenfalls erfolgreich validiert.
In der vorliegenden Forschungsarbeit wurde eine neue Konstruktion des DR für die kommerzielle Anwendung entwickelt und validiert. Nebenbei wurde der Auswerteprozess zur Berechnung der diffusionsbereinigten Wirkstofffreisetzung vereinheitlicht und validiert. Zuletzt wurde das Anwendungsgebiet des DR von parenteralen Nanoformulierungen auf halbfeste Arzneiformen erweitert.
Der erste Teil der vorliegenden Arbeit beinhaltet die funktionelle Analyse von fünf Oberflächenproteinen von B. recurrentis die die Fähigkeit besitzen, die Aktivierung von humanen Komplement zu inhibieren und Borrelien vor Bakteriolyse zu schützen. Im zweiten Teil der Arbeit wurden zwei immunologische Testverfahren mit hoher Sensitivität sowie Spezifität entwickelt und mit zahlreichen Patientenseren evaluiert. Die entwickelten Tests könnten in Zukunft als zuverlässige Instrumente für eine gesicherte Diagnose von LRF eingesetzt werden.
Eine Sequenzanalyse führte zur Identifizierung eines neuen Proteinclusters, welches die fünf untersuchten Komplement-inhibierenden Proteine als „Cluster of Complement-targeting and Host-interacting Proteins“ oder „Chi-Gencluster“, zusammenfasst. Diese Oberflächenproteine wurden als ChiA, ChiB, ChiC, ChiD und ChiE bezeichnet. Weiterführende Sequenzanalysen ergaben, dass das Chi-Gencluster extrem hoch konserviert ist und sowohl in den ersten B. recurrentis-Isolaten aus den 1990er Jahren als auch in B. recurrentis-Stämmen nachgewiesen werden konnte, die 2015 aus Patienten isoliert wurden.
Durch funktionelle Analysen konnte gezeigt werden, dass alle fünf Chi-Proteine in der Lage sind den alternativen und terminalen Komplementweg zu inhibieren. Ebenfalls konnte für die Proteine ChiB, ChiD sowie ChiE nachgewiesen werden, dass die Interaktion mit der Komplementkomponente C5 dosisabhängig verläuft.
Die strukturelle Aufklärung des Proteins ChiB ermöglichte es Aminosäuren zu identifizieren, von denen angenommen wurde, dass sie für die Interaktion mit Komplement eine Rolle spielen könnten. Durch in vitro Mutagenese konnten insgesamt fünf verschiedene Varianten von ChiB generiert werden, die jedoch keine Veränderungen in ihrem Komplement-inhibierenden Potential gegenüber dem unveränderten ChiB-Protein aufwiesen. Weder in der Inhibition des alternativen oder des terminalen Komplementweges, noch in der Interaktion mit den untersuchten Komplementkomponenten C3b, C5 und C9.
Weiter konnte gezeigt werden, dass die lytische Aktivität von Humanserum durch Vorinkubation mit ChiB, ChiC, ChiD und ChiE drastisch reduziert werden konnte, sodass Serum-sensible Borrelienzellen in Gegenwart von Komplement überlebten. „Gain-of-function“ B. garinii-Transformanten, welche mit dem entsprechendem Chi-kodierenden Gen transformiert wurden, bestätigten die mit den gereinigten Proteinen erhobenen Ergebnisse.So konnte nachgewiesen werden, dass ChiB-, ChiC- oder ChiD-produzierende „Gain-of-function“ B. garinii Transformanten, nicht jedoch ChiE- produzierende Zellen, in der Lage waren einen Serum-resistenten Phänotypen auszubilden. Für Transformanten, die zwei-, drei- oder vier Chi-Proteine in verschiedenen Kombinationen gleichzeitig produzierten, konnte allerdings die Fähigkeit in Gegenwart von Humanserum zu überleben nicht bestätigt werden.
Molekulare Analysen mit verschiedenen RF-Borrelienstämmen führten zum Nachweis, dass die fünf Chi-kodierenden Gene bei allen Isolaten vorhanden sind und unter in vitro Bedingungen exprimiert werden. Im Gegensatz zu B. recurrentis PAbJ, ließ sich das HcpA kodierende Gen in B. duttonii LAI nicht nachweisen, jedoch alle dem Chi-Cluster zugehörigen Gene. Bei B. duttoni V fehlte das gesamte Chi-Cluster sowie die für CihC- und HcpA-kodierenden Gene. Durch eine Western Blot-Analyse konnte mit spezifischen Antikörpern bestätigt werden, dass die Proteine CihC, HcpA und ChiB in B. recurrentis A17 unter in vitro Bedingungen produziert wurden.
Im zweiten Teil der vorliegenden Arbeit wurden durch die Analyse der IgM- und IgG-Immunreaktivitäten der LRF-Patientenseren zwei Proteine identifiziert, CihC und GlpQ, die als potenzielle Antigene für die Serodiagnostik des LRF evaluiert wurden. Eine initiale Evaluierung des IgM Lineblot-Immmunoassays zeigte jedoch nur eine geringe Sensitivität für die beiden Antigene, während der IgG Lineblot-Immunoassay eine sehr hohe Sensitivität aufwies. Der ELISA hingegen zeigte bei einer Kombination beider Antigene sehr gute Sensitivitäten und Spezifitäten. Um die starke Hintergrundfärbung bei den Lineblot-Immunoassays, welche eine korrekte Bewertung der Reaktivitäten gegenüber CihC erheblich erschwerten, zu minimieren, wurde ein „Epitop-Mapping“ durchgeführt, um immunogene Regionen innerhalb des CihC-Proteins zu lokalisieren. Eine zweite Evaluierung mit dem immunreaktiven N-terminalen CihC-Fragment CihC-N führte zu einer deutlichen Verbesserung der IgG Lineblot-Immunoassays mit einer Sensitivität von 100 % und einer starken Reduktion der Hintergrundfärbung. Zusätzlich konnte die Sensitivität der IgM-ELISA deutlich verbessert werden. Die Verwendung von CihC-N führte beim IgG-ELISA zur Herabsetzung des Cut-off-Wertes und zu einer besseren Unterscheidung zwischen den positiven LRF-Seren und den verwendeten Kontrollseren. Im Rahmen dieser Arbeit konnten somit zwei serologische in vitro Diagnostika entwickelt werden, die als zuverlässige Point-of-Care-Diagnostik in klinischen Studien eingesetzt werden könnten. Zur Steigerung der Sensitivität des IgM-Lineblot-Immunoassays sollten allerdings weiterführende Untersuchungen mit weiteren immunreaktiven Antigenen, wie z.B. den Vmp-Proteinen von B. recurrentis, angestrebt werden.
Im Rahmen dieser Arbeit wurde die schnelle Energietransfer- (EET) und Elektronentransfer (ET)-Dynamik unterschiedlichster Quantenpunkte (QD) spektroskopisch untersucht. Die untersuchten Systeme bestanden in den meisten Fällen aus Donor-Akzeptor-Paaren, bei denen die Halbleiternanokristalle als Donor fungierten. Der Fokus lag dabei auf der gezielten Anpassung des Donors, um die optimale Funktionalität zu erreichen. Die Untersuchung der Nanokristalle erstreckte sich daher von einfachen Kernen über verschiedene Kern-Schale-Partikel bis hin zu völlig anderen Strukturen wie Nanoplatelets (NPL). Als Akzeptor wurden eine Vielzahl von Molekülen verwendet, die sich als Elektronen- und/oder Energieakzeptoren für die verschiedenen QDs eignen.
Structure-function relationships in substrate binding protein dependent secondary transporters
(2023)
This work provides new insights into the relevance of SBP dependent secondary transport systems, especially in the thus far under-researched subgroup of TAXI transporters. Importantly, we identified and characterized the TAXI transport system TAXIPm-PQM from Proteus mirabilis. We demonstrated that, in contrast to previously characterized SBP dependent secondary transport systems, TAXIPm-PQM is a proton coupled system and transports the C5-dicarboxylate α- ketoglutarate. Since initially the transport of α-ketoglutarate could only be demonstrated in vivo but not in vitro using established protocols (Mulligan et al. 2009), we investigated in detail the differences between the in vivo and in vitro assay. This resulted in a bioinformatic analysis of TRAP and TAXI signal peptides, which strongly implied that TAXIPm-P requires a transmembrane anchor to allow for transport. We then provided TAXIPm-P surface tethered to the membrane in in vitro transport assays and confirmed the prediction of our bioinformatic analysis that TAXIPm-PQM deploys a membrane-anchored instead of a soluble SBP. Furthermore, the TAXI transport system TAXIMh-PQM from Marinobacter hydrocarbonoclasticus transports fumarate only if both membrane domains Q and M are present. For further characterization, Michaelis-Menten kinetics and affinities were determined for both TAXI transport systems TAXIPm-PQM from Proteus mirabilis and TAXIMh-PQM from Marinobacter hydrocarbonoclasticus. In addition, nanobodies were selected for the membrane domain TAXIPm-QM from Proteus mirabilis to stabilize different conformations which can serve in subsequent structural elucidation studies. Furthermore, the TRAP SBP TRAPHi-SiaP from Haemophilus influenzae was shown to interact not only with its corresponding membrane domain TRAPHi-SiaQM but with at least one additional transporter. It was thereby excluded that TRAPHi- SiaP transfers N-acetylneuraminic acid to the only native E. coli TRAP transporter TRAPEc-YiaMNO and suggested to rather interact with a SBP dependent ABC transport system as this protein family represents the largest SBP dependent protein group in E. coli (Moussatova et al. 2008).
Baleen whales (Mysticeti) are a clade of highly adapted carnivorous marine mammals that can reach extremely large body sizes and feature characteristic keratinaceous baleen plates used for obligate filter feeding. From a conservation perspective, nearly all baleen whale species were hunted extensively over a roughly 100 years lasting time period that depleted many of the respective whale stocks with so far unknown consequences for e.g. their molecular viability. From an evolutionary perspective, the lack of fossil records together with conflicting molecular patterns resulted in a still unclear and debated phylogeny of modern baleen whales, particularly in rorquals (Balaenopteridae). In this dissertation, I will demonstrate the application of baleen whale genomes to tackle these open questions by using modern approaches of conservation and evolutionary genomics.
Conservation genomic aspects of baleen whales were addressed in two projects, both using whole genome data of either an Icelandic fin whale (Balaenoptera physalus) population or multiple blue whale (Balaenoptera musculus) populations to evaluate the impact of the industrial whaling era on their molecular viability. The results suggest a substantial drop in effective population size of both species but also a lack of manifestation in genotypes of the fin whale population when compared to the blue whale populations. Especially the rare and short runs of homozygosity (ROH), usually indicative for inbreeding, suggest frequent outcrossing in fin whales while all analyzed blue whale populations featured long and frequent ROH. In addition to these analyses, genome data of blue whale populations was further used to evaluate if northern hemisphere blue whales diverged into different subspecies. Population genetic and gene flow analyses showed clearly separated and well isolated populations in accordance with their assumed geographical distance. In contrast, the genome-wide divergence between all blue whale populations was low compared to other cetacean populations and to the next closely related sei whale species. Because this includes the morphologically different and well recognized pygmy blue whale subspecies, a proposal was made to equally categorize the two northern-hemisphere blue whale populations as subspecies.
Evolutionary aspects were addressed in a third project, by constructing the genome of the pygmy right whale (Caperea marginata) and testing its potential in phylogenetics and cancer research. Phylogenomic analyses using fragments of a whole-genome alignment featuring nearly all extant baleen whales, allowed the revision of the complex evolutionary relationships of rorquals by quantifying and characterizing the amounts of conflicts in early diverging branches. These relationships were further used to identify phylogenetically independent pairs of baleen whales with a maximum of diverging body size differences to compare rates of positive selection between their genomes. The results suggest nearly evenly distributed frequencies of alternative topologies which supports the representation of the early divergence of rorquals as a hard polytomy with high amounts of introgression and incomplete lineage sorting. Within the set of available genomic data, three independent pairs of baleen whales with diverging body sizes were found and comparisons of positive selection rates resulted in many potentially body size and cancer related genes. The lack of conserved selection patterns, however, suggest a more convergent evolution of size and cancer resistance like previously discussed in paleontology.
In conclusion, the application of whole genome data using methods of conservation genetics allowed for a comprehensive estimation about the molecular viability of blue and fin whales as well as an assessment of the taxonomic status of northern-hemisphere blue whale populations. The rather different results between blue and fin whales underlines the importance of genomic monitoring of baleen whales because different species show rather different molecular consequences of their potentially varying depletions. Furthermore, as showcased for the northern-hemisphere blue whale, many important isolated populations of baleen whales may still be unknown to conservation management and genome-wide comparisons will most likely contribute to overcome this under-classification problem. The application of whole genome data in evolutionary research allowed the characterization of the complex patterns of molecular conflicts within baleen whales and especially rorquals that will contribute to the still rather unclear understanding of their evolution. The here found molecular support for the idea of convergent evolution of gigantism in whales will further guide the search for molecular patterns responsible for Peto’s paradox.
Compaction and spheroid formation modulates stemness and differentiation of human pancreas organoids
(2023)
The incidence of diabetes type 1 (T1D) in children and young adults is increasing worldwide. T1D is well treated by insulin administration. However, there is currently no long-lasting cure for this ailment. The success rate of pancreatic islet transplantation to treat T1D is limited by the availability of patient-matched islets and the necessity of using life-long immunosuppressive medication. The difficulties caused by transplantation can be overcome by generating bio-engineered pancreatic islets from patient-derived progenitor cells. Aim of this thesis is to establish new strategies for the generation and analysis of pancreatic lineages derived from human progenitor cells. It reports on the optimization of a technique to form human pancreatic spheroids from hollow monolayered human pancreas organoids (hPOs) to investigate how cell-cell and cell-matrix interaction can be leveraged to induce endocrine differentiation of the pancreas progenitor cell organoids. We introduce cell aggregation protocols to generate endocrine pancreas cell lineages from ductal pancreatic cells. Next, we study the effect of co-culture with stromal and endothelial cells to promote cell differentiation toward a pancreatic fate enhancing β cells productivity.
This thesis has focused on identifying the differences in gene expression along with phenotypical transformation during differentiation of human pancreatic organoids (hPOs) towards human β cells to be used in the future of cellular therapeutics in treating T1D patients.
N6-methyladenosine (m6A) is the most abundant and well understood modification in eukaryotic mRNA and was first identified in polyadenylated parts of the mRNA.The distinct distribution of m6A in the transcriptome with special enrichment in long internal exons, 39UTRs and around stop codons was uncovered by early biochemical work and later on antibody based sequencing techniques. The so called m6A writer, reader and eraser machinery is responsible for the dynamic and with that regulatory nature of the m6A modification. As m6A writer, the human N6-methyltransferase complex (MTC) cotranscriptionally methylates the central adenine within a RRACH (preferably GGACU) sequence context to form m6A in the nascent RNA chain.9–15 The catalytic core of the complex is formed by the two proteins METTL3 and METTL14, with the active site located in the methyltransferase domain (MTD) of METTL3.16–18 The DPPW motif near the methyl donor S-adenosylmethionine (SAM) binding site in this MTD was postulated to bind the target adenine during catalysis. Moreover, a positively charged groove in the METTL3-METTL14 interface, the C-terminal RGG domain in METTL14 and the zinc finger motifs in METTL3 were identified as important domains for RNA binding. However, to date there are no full-length or substrate-RNA-bound structures of the catalytic METTL3-METTL14 complex.
In addition, a set of accessory proteins assembles to the METTL3-METTL14 heterodimer to form the full MTC, mediated by WTAP that firmly binds to the N-terminal leader helix in METTL3.20 WTAP was shown to locate the whole complex to the nuclear speckles and can modulate m6A deposition to specific sites in the RNA. Moreover, WTAP acts as binding platform for other accessory proteins including VIRMA, RBM15, ZC3H13 and HAKAI that are mostly identified to mediate position specific methylation. For example, RBM15 was shown to mediates region-selective methylation in a WTAP dependent manner, directing specificity towards U-rich sequences.
The observed specificity of the methyltransferase complex to methylate only site specific DRACH sequenced is still poorly understood. Some possible modulators like the role of the accessory proteins are under investigation, however, the structural context of the RNA methylation sites or a structural preference of the complex have been mainly neglected so far. Moreover, the structural dynamics of this methylation process still remain elusive. This thesis contributes to the afore-mentioned aspects by analysis of the methylation process regarding RNA structure sensitivity with enzymatic activity assays and its dynamic nature by implementing a smFRET approach.
We hypothesized the target RNA secondary structure to be an additional important modulator of methylation efficiency, based on the RNA binding elements of the complex (positively charged binding groove, zinc finger domain, RGG domain) and the supposed target adenine binding in the active site. Here, we postulated the possibility for a flipped-out adenine to be of special relevance, which is closely related to the local stability of the target adenine containing structure. Moreover, efficient binding of the protein complex to the RNA should require the ability to anchor the RNA on both sides of the target sequence.
The production of ribosomes is a complicated multistep, that is susceptible to changes occurring within the cell and its environment. The process itself requires many proteins, known as ribosome biogenesis factors (RBFs) and many non-coding RNAs like the small nucleolar RNAs (snoRNAs). While RBFs are required for the accurate processing of the pre-rRNA into mature rRNAs, the snoRNAs act to coordinate and guide enzymes for post-transcriptional modifications, chiefly 2´-O-ribose methylation and pseudouridylation. While ribosome biogenesis is mostly described in human and yeast model eucaryotes, similar detailed studies in the model plant Arabidopsis thaliana are far less explored and understood. Furthermore, for many experimentally confirmed modification sites the according snoRNAs and for many pre-rRNA processing steps the responsible RBFs are missing. Therefore, it is expected that a high number of snoRNAs and RBFs are not identified till yet. For this reason, RNA-deep sequencing was performed in order to identify novel snoRNAs and MS analysis data of nucleoli and nuclei of A. thaliana from a former PhD student were used in order to find new proteins involved in pre-rRNA processing.
In here, it is shown that with RNA deep-sequencing still new snoRNAs and snRNAs can be identified and that detection of predicted snoRNAs can be fulfilled with a) antisense oligonucleotides tagged with fluorescence dyes and b) with radioactive labeled antisense probes. Furthermore, a secondary structure map of the 60S and 40S subunit highlighting the predicted and moreover verified modification sites in 5.8S, 25S and 18S rRNA was created. Especially, the correlation between the modification sites and the guiding snoRNA is highlighted further shedding light on overview about current pre-rRNA modification sites and corresponding guiding snoRNAs. The next chapter reveals the complex and multi-layered existence of the 5.8S rRNA and its numerous precursors. The mutant prp24 (also known as seap1) encoding AtPRP24, is recognized as factor being important for splicing as it is promoting the recruitment of the U4 and U6 snRNAs to the spliceosome. In here, it was found that AtPRP24 is involved in processing of 5.8S rRNA precursors, recognizable by precursors that are over accumulating in the mutant. Moreover, it could be shown for the first time that the plant-specific precursor 5´-5.8S is exported to the cytoplasm, where final cleavage steps of 5.8S rRNA takes place. In the prp24.2 mutant, this precursor is exported at an increased rate to the cytoplasm, where it can be detected in the actively translating ribosomes (polysomes). A lower sensitivity of the mutant seeds to cycloheximide (CHX) suggests that due to the extension at the 5´-end of 5.8S, the structure of the 60S subunit has altered CHX binding. In conclusion, this work highlights the importance and complexity of 5.8S rRNA and its precursors for ribosome biogenesis and displays new insights into pre-rRNA processing in A. thaliana.
Xylose, an abundant sugar fraction of lignocellulosic biomass, is a five-carbon skeleton molecule. Since decades, utilization of this sugar has gained much attention and has been in particular focus as a substrate for production of biofuels like ethanol by microbial hosts, including Saccharomyces cerevisiae. In this yeast, xylose is naturally not used as a carbon source, but its utilization could be achieved by metabolic engineering either via the oxidoreductive route or through the isomerase pathway. Both pathways share xylulose as a common intermediate that must be phosphorylated before entering the endogenous metabolism via the non-oxidative pentose phosphate pathway (noxPPP). Besides this, in some bacteria a non-phosphorylating oxidative pathway for xylose degradation exists, known as Weimberg pathway, where a molecule of xylose is converted by a series of enzymes - xylose dehydrogenase (XylB), xylonate dehydratase (XylD), 3-keto-2-deoxy-xylonate dehydratase (XylX) and α-ketoglutarate semialdehyde dehydrogenase (KsaD) - to form α-ketoglutarate (AKG). Besides having several useful properties as a product, AKG could also be used for cell growth as an intermediate of the tricarboxylic acid (TCA) cycle. One target of the present study is to establish a functional Weimberg pathway in S. cerevisiae. Previous studies have shown that this task is not trivial, for instance due to the toxicity of xylonate (the first metabolite of the pathway) and the involvement of an iron-sulfur cluster dependent enzyme, the D-xylonate dehydratase. The assembly of iron-sulfur clusters on a heterologous protein in yeast is known to be challenging.
To establish the Weimberg pathway in yeast, the genes xylB, xylD, and xylX were obtained from Caulobacter cresentus and ksaD was from Corynebacterium glutamicum. In a variant, the dehydratase xylD was replaced with orf41 from Arthrobacter nicotinovorans, which is believed to be independent of iron-sulfur clusters. Growth of yeast cells on xylose as a sole carbon source was expected as an indicator of a functional Weimberg pathway. However, the heterologous expression of the codon optimized genes was not sufficient to reach this goal. Due to the complexity of the interactions of the heterologous pathway with the endogenous cellular processes, it was assumed that potential limitations could be overcome by adaptive laboratory evolution, using xylose as a sole source of carbon. Increasing selection pressure was applied on a strain with Weimberg pathway genes integrated into the genome over several generations. As a variant of the evolutionary engineering approach, mutator strains were generated. For this, RAD27 and MSH2 genes were deleted, which are involved in nucleotide excision and mismatch repair mechanisms, respectively. Some of the resulting strains PRY24, PRY25, PRY27 and PRY28 were able grow in xylose as a sole carbon source after evolutionary engineering. As a control, a non-mutator strain PRY19 was also included. Strikingly, only the mutator strains were able to consume xylose as a sole carbon source, which shows the feasibility of the approach.
In addition to the mutator strain strategy, a further approach employed in the present study was the simultaneous expression of the Weimberg pathway in the cytosol and mitochondria. This was based on the reasoning that the iron-sulfur cluster biogenesis on XylD may be improved in the organelle and that the AKG is an intermediate of the TCA cycle. In the strain AHY02, all enzymes of the pathway were tagged with mitochondrial targeting signals in addition to a full cytosolically localized pathway. The localization of the mitochondrial variants was confirmed by fluorescence microscopy. Together with AHY02, CEN.PK2-1C wild type strain was also included as a control for evolution. When a selection pressure on xylose was applied, both strains - AHY02 and CEN.PK2-1C - were able to grow in the course of evolution. Deletion of the xylulokinase (XKS1) gene was found to be detrimental for both evolved strains in xylose-containing media. This suggests that the evolution of the endogenous oxidoreductive and noxPPP genes is responsible for growth of the evolved cells. For the evolved strain AHY02, it could also be possible that the Weimberg pathway genes supported to growth in addition to the oxidoreductive route. To elucidate the underlying molecular mechanisms, genome sequencing and reverse engineering approaches would be necessary in future.
In addition to screening for growth on xylose as a sole carbon source, a less stringent screening system was created to examine even a minor flux of xylose towards AKG. For this, all genes necessary for conversion of isocitrate to AKG where deleted, yielding a glutamate auxotrophic strain. In this system, the cells can grow on other carbon sources, whereas xylose is only provided as a source of AKG for the synthesis of glutamate...